ADIL — ADIAL PHARMACEUTICALS, INC.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2018-07-27.
Performance
Technicals
Others in Healthcare
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-07-16 | Coastlands Capital LP 10% owner | Open-market purchase | 1.2K | 2.75 | 3.4K |
| 2026-07-14 | Coastlands Capital LP 10% owner | Open-market purchase | 2.0K | 2.65 | 5.3K |
| 2026-07-10 | Coastlands Capital LP 10% owner | Open-market purchase | 1.7K | 2.70 | 4.6K |
| 2026-07-09 | Coastlands Capital LP 10% owner | Open-market purchase | 10.1K | 2.79 | 28.0K |
| 2026-06-29 | Coastlands Capital LP 10% owner | Open-market purchase | 25.0K | 2.60 | 65.0K |
| 2026-06-12 | Davidson Matt Chief Development Officer | Grant or award | 232.4K | 0.00 | 0 |
| 2026-06-11 | Davidson Matt Chief Development Officer | Grant or award | 1.8K | — | — |
| 2026-06-11 | Davidson Matt Chief Development Officer | Grant or award | 61.6K | — | — |
| 2026-06-11 | Davidson Matt Chief Development Officer | Grant or award | 3.4K | — | — |
| 2026-06-11 | Davidson Matt Chief Development Officer | Grant or award | 101 | — | — |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | 43.4K | 24.2K |
| VANGUARD FIDUCIARY TRUST CO | 10.5K | 5.9K |
| Manchester Capital Management LLC | 3.4K | 1.9K |
| Tower Research Capital LLC (TRC) | 2.4K | 1.4K |
| BlackRock, Inc. | 2.0K | 1.1K |
| UBS Group AG | 970 | 542 |
| VANGUARD CAPITAL MANAGEMENT LLC | 646 | 361 |
| MORGAN STANLEY | 90 | 50 |
| SBI Securities Co., Ltd. | 84 | 47 |
| Caitong International Asset Management Co., Ltd | 27 | 15 |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Latest SEC filings
| form | filed | period | |
|---|---|---|---|
| 10-Q | 2026-08-14 | 2026-06-30 | on EDGAR ↗ |
| 8-K | 2026-08-13 | 2026-08-10 | on EDGAR ↗ |
| PRE 14A | 2026-08-11 | 2026-08-10 | on EDGAR ↗ |
| 8-K/A | 2026-08-11 | 2026-06-11 | on EDGAR ↗ |
| 4 | 2026-07-16 | 2026-07-14 | on EDGAR ↗ |
| 4 | 2026-07-13 | 2026-07-09 | on EDGAR ↗ |
| SCHEDULE 13G/A | 2026-07-01 | — | on EDGAR ↗ |
| 4 | 2026-07-01 | 2026-06-29 | on EDGAR ↗ |
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Adial Pharmaceuticals, Inc. (ADIL) filed form 8-K · 2026-08-21 · SEC EDGAR
- Adial Pharmaceuticals, Inc. (ADIL) filed form 8-K · 2026-08-17 · SEC EDGAR
- Adial Pharmaceuticals GAAP EPS of -$11.25 misses by $8.60 · 2026-08-17
- ADIAL PHARMACEUTICALS, INC. (ADIL) filed form 10-Q · 2026-08-14 · SEC EDGAR
- Adial Pharmaceuticals, Inc. (ADIL) filed form 8-K · 2026-08-13 · SEC EDGAR
- ADIAL PHARMACEUTICALS, INC. (ADIL) filed form 8-K · 2026-08-13 · SEC EDGAR
Ask the AI about ADIL
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →